Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
Secukinumab in plaque psoriasis--results of two phase 3 trials.
- R. Langley, B. Elewski, +17 authors C. Papavassilis
- Medicine
- The New England journal of medicine
- 23 July 2014
BACKGROUND
Interleukin-17A is considered to be central to the pathogenesis of psoriasis. We evaluated secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with… Expand
Psoriasis: epidemiology, clinical features, and quality of life
- R. Langley, G. Krueger, C. Griffiths
- Medicine
- Annals of the rheumatic diseases
- 11 February 2005
Psoriasis is a common chronic, recurrent, immune mediated disease of the skin and joints. It can have a significant negative impact on the physical, emotional, and, psychosocial wellbeing of affected… Expand
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.
- M. Lebwohl, B. Strober, +32 authors Ajay Nirula
- Medicine
- The New England journal of medicine
- 30 September 2015
BACKGROUND
Early clinical studies suggested that the anti-interleukin-17 receptor A monoclonal antibody brodalumab has efficacy in the treatment of psoriasis.
METHODS
In two phase 3 studies… Expand
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.
BACKGROUND
Adalimumab is a fully human monoclonal antibody that binds tumor necrosis factor, a key proinflammatory cytokine involved in the pathogenesis of psoriasis.
OBJECTIVE
We sought to… Expand
Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment.
- R. Langley, C. Ellis
- Medicine
- Journal of the American Academy of Dermatology
- 1 October 2004
BACKGROUND
Reliable assessment of severity in psoriasis is essential to document treatment responses in clinical research. The reliability of current clinical outcome measures is uncertain.
… Expand
Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)
- Jean-Hilaire Saurat, G. Stingl, +6 authors A. Camez
- Medicine
- The British journal of dermatology
- 28 November 2007
Background Biologic therapies such as adalimumab, a tumour necrosis factor antagonist, are safe and effective in the treatment of moderate to severe chronic plaque psoriasis.
Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study.
- K. Gordon, R. Langley, +10 authors M. Okun
- Medicine
- Journal of the American Academy of Dermatology
- 1 October 2006
BACKGROUND
Tumor necrosis factor is pivotal in the pathogenesis of psoriasis. Adalimumab is a fully human monoclonal immunoglobulin G1 antibody that neutralizes tumor necrosis factor.
OBJECTIVES
We… Expand
A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis.
- G. Krueger, R. Langley, +5 authors M. Lebwohl
- Medicine
- The New England journal of medicine
- 8 February 2007
BACKGROUND
Skin-infiltrating lymphocytes expressing type 1 cytokines have been linked to the pathophysiology of psoriasis. We evaluated the safety and efficacy of a human interleukin-12/23 monoclonal… Expand
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
- K. Papp, R. Langley, M. Lebwohl, G. Krueger, F. T. P. 2. S. investigators
- Medicine
- The Lancet
- 23 May 2008
BACKGROUND
Ustekinumab, a human monoclonal antibody against interleukins 12 and 23, has shown therapeutic potential for psoriasis. This study assessed the efficacy and safety of ustekinumab in… Expand
Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey.
- M. Lebwohl, H. Bachelez, +7 authors P. V. D. van de Kerkhof
- Medicine
- Journal of the American Academy of Dermatology
- 1 May 2014
BACKGROUND
Available psoriasis surveys offer valuable information about psoriasis and psoriatic arthritis (PsA), but are limited by methodology or enrollment requirements.
OBJECTIVE
To further the… Expand